Clinical Trials
121 trialsStudy of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
LuPARP
Vastra Gotaland Region
TraveraRTGx
Travera Inc
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
MesoPDT
University Hospital, Lille
DREAM3R
PrECOG, LLC.
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
BIMES
Fundación GECP
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
TRuST
Ipsen
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
MK-3475-A17
Merck Sharp & Dohme LLC
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
NERO
University Hospital Southampton NHS Foundation Trust
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
CONFIRM
University of Southampton
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
ROOT
Taproot Health
IMPROVE-I
Radboud University Medical Center
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
University of Chicago
CheckMate743
Bristol-Myers Squibb
DENIM
Amphera BV
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Massachusetts General Hospital
ATOMIC
Polaris Group
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
CanBenefitII
University of Hull
MpeTK01
Candel Therapeutics, Inc.
PrE0505
PrECOG, LLC.
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
MAPS
Intergroupe Francophone de Cancerologie Thoracique
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
DUET-2
Xencor, Inc.
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
IMPROVE-III
Radboud University Medical Center
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University